Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cardiff Oncology, Inc.

NASDAQ: CRDF · Life Sciences · 5 alerts · CIK 1213037

Share price
$0.8477Close, Nov 16
Market cap
$65.9M
Shares outstanding
77.8MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cardiff Oncology, Inc. filings on SEC EDGAR ↗

4:22 PM ET 8-K
Financial Results

Cardiff Oncology Financial Results

Cardiff Oncology reported Q3 2026 financial results and provided a clinical update on its Phase 2 trial of onvansertib in first-line RAS-mutated mCRC, noting that median PFS has not yet been reached in the 30 mg arm. The company is preparing for a registrational Phase 3 trial expected to start in Q1 2027 and reported a cash position of $68.1 million as of September 30, 2026.

Term
Q3 2026

“We’re greatly encouraged by the performance of onvansertib in first-line RAS-mutated mCRC. As the data mature, the benefit of onvansertib in combination with FOLFIRI/bev is becoming more evident, with growing separation between the onvansertib and control arms.”

Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology

“Building on the strength of these data, we are actively preparing for our upcoming registrational trial. There are currently no treatment options specifically approved for patients with pan RAS-mutated mCRC in the first-line setting and we believe onvansertib has the potential to become an important new treatment for these patients.”

Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology
4:21 PM ET 10-Q
Financial Results

Cardiff Oncology Q3 2026 Results: Net Loss of $8.86M, Loss Narrows

Cardiff Oncology reported a net loss of $30.4 million for the nine months ended September 30, 2026, compared to $38.6 million in the prior year period. The company strengthened its balance sheet through the issuance of common stock and warrants, raising approximately $9.1 million in net proceeds during the third quarter of 2026.

Key figure
Net loss $8.86M
4:44 PM ET 8-K
Leadership Change

Cardiff Oncology Leadership Change

Dr. Roger Sidhu has stepped down as Chief Medical Officer of Cardiff Oncology in a mutually agreed transition. Dr. Leila Alland has been appointed as interim Chief Medical Officer effective October 23, 2026, and will receive a monthly consulting fee of $35,000.

4:30 PM ET 8-K
Other 8-K Filing

Cardiff Oncology Other 8-K Filing

Cardiff Oncology stockholders approved an amendment to the company's Certificate of Incorporation to double the number of authorized shares of common stock from 150 million to 300 million. The vote took place at a Special Meeting on October 22, 2026, with approximately 78% of voted shares in favor. This increase in authorized capital provides the company with additional shares for future corporate purposes, such as financing or strategic transactions.

9:28 AM ET 8-K
Court & Legal Update

Cardiff Oncology Court & Legal Update

Cardiff Oncology entered into a confidential settlement agreement with Nerviano Medical Sciences to resolve litigation in the U.S. District Court for the Southern District of California regarding patent inventorship and license performance. As part of the settlement, the parties amended their 2017 license agreement for onvansertib, updating the royalty structure, exclusivity framework, and granting Nerviano a board observer seat. No monetary payments were made by either party to settle the litigation, which will be dismissed with prejudice.

Counterparty
Nerviano Medical Sciences, S.r.l.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.